PL103082B1 - Sposob wytwarzania nowego preparatu antygenowego - Google Patents

Sposob wytwarzania nowego preparatu antygenowego Download PDF

Info

Publication number: PL103082B1
Authority: PL; Poland
Prior art keywords: antigenic protein; lipid; microbubbles; layer; mixed
Prior art date: 1975-09-29

Application number

PL1976192701A

Other languages

English (en)

Polish (pl)

Original Assignee

Wellcome Foundation Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1975-09-29

Filing date

1976-09-28

Publication date

1979-05-31

1976-09-28 Application filed by Wellcome Foundation Ltd filed Critical Wellcome Foundation Ltd

1979-05-31 Publication of PL103082B1 publication Critical patent/PL103082B1/pl

Links

238000002360 preparation method Methods 0.000 title claims description 23
238000004519 manufacturing process Methods 0.000 title claims description 7
102000036639 antigens Human genes 0.000 title description 10
108091007433 antigens Proteins 0.000 title description 10
239000000427 antigen Substances 0.000 title description 9
102000004169 proteins and genes Human genes 0.000 claims description 60
108090000623 proteins and genes Proteins 0.000 claims description 60
238000000034 method Methods 0.000 claims description 51
150000002632 lipids Chemical class 0.000 claims description 44
230000000890 antigenic effect Effects 0.000 claims description 43
239000002502 liposome Substances 0.000 claims description 43
239000002356 single layer Substances 0.000 claims description 25
241000700605 Viruses Species 0.000 claims description 24
239000010410 layer Substances 0.000 claims description 23
239000000243 solution Substances 0.000 claims description 18
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical group ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 14
239000000203 mixture Substances 0.000 claims description 14
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
238000002156 mixing Methods 0.000 claims description 10
239000007864 aqueous solution Substances 0.000 claims description 9
230000015572 biosynthetic process Effects 0.000 claims description 9
235000010445 lecithin Nutrition 0.000 claims description 9
239000000787 lecithin Substances 0.000 claims description 9
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 8
229940067606 lecithin Drugs 0.000 claims description 8
238000002604 ultrasonography Methods 0.000 claims description 8
229910019142 PO4 Inorganic materials 0.000 claims description 7
239000010452 phosphate Substances 0.000 claims description 7
241000712461 unidentified influenza virus Species 0.000 claims description 7
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 6
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 6
239000002904 solvent Substances 0.000 claims description 6
244000052769 pathogen Species 0.000 claims description 4
238000000108 ultra-filtration Methods 0.000 claims description 4
241000894006 Bacteria Species 0.000 claims description 3
235000012000 cholesterol Nutrition 0.000 claims description 3
239000012299 nitrogen atmosphere Substances 0.000 claims description 2
239000003623 enhancer Substances 0.000 claims 2
125000001165 hydrophobic group Chemical group 0.000 claims 2
244000000010 microbial pathogen Species 0.000 claims 2
241000699670 Mus sp. Species 0.000 description 17
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
230000004520 agglutination Effects 0.000 description 11
210000004369 blood Anatomy 0.000 description 11
239000008280 blood Substances 0.000 description 11
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
238000002347 injection Methods 0.000 description 6
239000007924 injection Substances 0.000 description 6
239000012267 brine Substances 0.000 description 5
239000011780 sodium chloride Substances 0.000 description 5
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 5
241000700198 Cavia Species 0.000 description 4
KKUKTXOBAWVSHC-UHFFFAOYSA-N Dimethylphosphate Chemical compound COP(O)(=O)OC KKUKTXOBAWVSHC-UHFFFAOYSA-N 0.000 description 4
241001465754 Metazoa Species 0.000 description 4
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
150000003904 phospholipids Chemical class 0.000 description 4
210000002966 serum Anatomy 0.000 description 4
239000000126 substance Substances 0.000 description 4
239000000725 suspension Substances 0.000 description 4
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
238000007792 addition Methods 0.000 description 3
210000004027 cell Anatomy 0.000 description 3
238000010790 dilution Methods 0.000 description 3
239000012895 dilution Substances 0.000 description 3
201000010099 disease Diseases 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
230000003053 immunization Effects 0.000 description 3
210000004072 lung Anatomy 0.000 description 3
238000003756 stirring Methods 0.000 description 3
229960005486 vaccine Drugs 0.000 description 3
230000003612 virological effect Effects 0.000 description 3
101710186708 Agglutinin Proteins 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
101710146024 Horcolin Proteins 0.000 description 2
101710189395 Lectin Proteins 0.000 description 2
101710179758 Mannose-specific lectin Proteins 0.000 description 2
101710150763 Mannose-specific lectin 1 Proteins 0.000 description 2
101710150745 Mannose-specific lectin 2 Proteins 0.000 description 2
102000005348 Neuraminidase Human genes 0.000 description 2
108010006232 Neuraminidase Proteins 0.000 description 2
241001494479 Pecora Species 0.000 description 2
206010037660 Pyrexia Diseases 0.000 description 2
241000220317 Rosa Species 0.000 description 2
239000000910 agglutinin Substances 0.000 description 2
239000007853 buffer solution Substances 0.000 description 2
RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
239000000969 carrier Substances 0.000 description 2
239000012141 concentrate Substances 0.000 description 2
229960003983 diphtheria toxoid Drugs 0.000 description 2
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
239000006185 dispersion Substances 0.000 description 2
229940079593 drug Drugs 0.000 description 2
239000003814 drug Substances 0.000 description 2
230000000694 effects Effects 0.000 description 2
210000003743 erythrocyte Anatomy 0.000 description 2
230000002209 hydrophobic effect Effects 0.000 description 2
238000002649 immunization Methods 0.000 description 2
206010022000 influenza Diseases 0.000 description 2
229910000402 monopotassium phosphate Inorganic materials 0.000 description 2
235000019796 monopotassium phosphate Nutrition 0.000 description 2
239000013642 negative control Substances 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
239000012071 phase Substances 0.000 description 2
239000002953 phosphate buffered saline Substances 0.000 description 2
PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 2
235000011164 potassium chloride Nutrition 0.000 description 2
239000001103 potassium chloride Substances 0.000 description 2
239000000047 product Substances 0.000 description 2
230000002035 prolonged effect Effects 0.000 description 2
230000002685 pulmonary effect Effects 0.000 description 2
241000894007 species Species 0.000 description 2
108020001572 subunits Proteins 0.000 description 2
241000234282 Allium Species 0.000 description 1
235000002732 Allium cepa var. cepa Nutrition 0.000 description 1
101710145634 Antigen 1 Proteins 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
238000011749 CBA mouse Methods 0.000 description 1
206010008570 Chloasma Diseases 0.000 description 1
241000701022 Cytomegalovirus Species 0.000 description 1
241001506042 Duck influenza virus Species 0.000 description 1
241000710198 Foot-and-mouth disease virus Species 0.000 description 1
208000004898 Herpes Labialis Diseases 0.000 description 1
206010025323 Lymphomas Diseases 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
201000005505 Measles Diseases 0.000 description 1
208000003351 Melanosis Diseases 0.000 description 1
206010065764 Mucosal infection Diseases 0.000 description 1
241000711386 Mumps virus Species 0.000 description 1
208000010359 Newcastle Disease Diseases 0.000 description 1
REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 1
206010067152 Oral herpes Diseases 0.000 description 1
241000709664 Picornaviridae Species 0.000 description 1
102000002067 Protein Subunits Human genes 0.000 description 1
241000282887 Suidae Species 0.000 description 1
108010067390 Viral Proteins Proteins 0.000 description 1
208000000260 Warts Diseases 0.000 description 1
239000002253 acid Substances 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
230000000172 allergic effect Effects 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
208000010668 atopic eczema Diseases 0.000 description 1
235000015278 beef Nutrition 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000012928 buffer substance Substances 0.000 description 1
244000309464 bull Species 0.000 description 1
229910052792 caesium Inorganic materials 0.000 description 1
TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical compound [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 1
AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
-1 cholesterol Chemical class 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
239000003599 detergent Substances 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
RNPXCFINMKSQPQ-UHFFFAOYSA-N dicetyl hydrogen phosphate Chemical compound CCCCCCCCCCCCCCCCOP(O)(=O)OCCCCCCCCCCCCCCCC RNPXCFINMKSQPQ-UHFFFAOYSA-N 0.000 description 1
229940093541 dicetylphosphate Drugs 0.000 description 1
229910001873 dinitrogen Inorganic materials 0.000 description 1
125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
239000008344 egg yolk phospholipid Substances 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
239000000835 fiber Substances 0.000 description 1
238000005242 forging Methods 0.000 description 1
238000009472 formulation Methods 0.000 description 1
244000144993 groups of animals Species 0.000 description 1
229940124452 immunizing agent Drugs 0.000 description 1
108700010900 influenza virus proteins Proteins 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
235000013372 meat Nutrition 0.000 description 1
239000012528 membrane Substances 0.000 description 1
238000002941 microtiter virus yield reduction assay Methods 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000002245 particle Substances 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
150000003905 phosphatidylinositols Chemical class 0.000 description 1
239000011148 porous material Substances 0.000 description 1
239000013641 positive control Substances 0.000 description 1
150000003141 primary amines Chemical class 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
239000000523 sample Substances 0.000 description 1
201000010153 skin papilloma Diseases 0.000 description 1
239000000779 smoke Substances 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
238000005728 strengthening Methods 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000013589 supplement Substances 0.000 description 1
238000010998 test method Methods 0.000 description 1
RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
238000005406 washing Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Immunology (AREA)
Mycology (AREA)
Microbiology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Dispersion Chemistry (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicinal Preparation (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

PL1976192701A 1975-09-29 1976-09-28 Sposob wytwarzania nowego preparatu antygenowego PL103082B1 (pl)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GB39857/75A GB1564500A (en)	1975-09-29	1975-09-29	Biological preparations

Publications (1)

Publication Number	Publication Date
PL103082B1 true PL103082B1 (pl)	1979-05-31

Family

ID=10411873

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL1976192701A PL103082B1 (pl)	1975-09-29	1976-09-28	Sposob wytwarzania nowego preparatu antygenowego

Country Status (15)

Country	Link
JP (1)	JPS5244228A ( )
AU (1)	AU514848B2 ( )
BE (1)	BE846681A ( )
BG (1)	BG34181A3 ( )
CA (1)	CA1079634A ( )
DD (1)	DD127598A5 ( )
DE (1)	DE2643641A1 ( )
ES (1)	ES451923A1 ( )
FR (1)	FR2325387A1 ( )
GB (1)	GB1564500A ( )
HU (1)	HU176180B ( )
NL (1)	NL7610736A ( )
PL (1)	PL103082B1 ( )
SE (1)	SE7610708L ( )
ZA (1)	ZA765817B ( )

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4148876A (en)	1975-09-29	1979-04-10	Burroughs Wellcome Co.	Biological preparations
US4196191A (en)	1975-09-29	1980-04-01	Burroughs Wellcome Co.	Biological preparations
FR2442241A2 (fr) *	1978-03-20	1980-06-20	Anvar	Nouveaux composes esters de muramyl-peptide, leur preparation et les compositions pharmaceutiques les contenant, notamment sous forme de liposomes
FR2420545A1 (fr) *	1978-03-20	1979-10-19	Anvar	Nouveaux esters de l'acide n-acetyl-muramyl-aminoacyl-glutamique ou des derives de substitution de celui-ci a proprietes anti-infectieuses et/ou d'adjuvants immunologiques
GB2026340B (en) *	1978-07-03	1982-12-22	Ash P	Stabilising microvesicles
US4201767A (en) *	1978-11-08	1980-05-06	Merck & Co., Inc.	Viral liposome particle
US4199565A (en) *	1979-03-26	1980-04-22	Merck & Co., Inc.	Liposome particle containing viral or bacterial antigenic subunit
HU184141B (en) *	1979-12-27	1984-07-30	Human Oltoanyagtermelo	Adjuvant particles compositions containing said particles and biologically active substances adsorbed thereon and a process for the preparation thereof
DE3173713D1 (en) *	1980-09-05	1986-03-20	Frappier Armand Inst	Formation of an immunosome exclusively made of viral antigens reconstituted on an artificial membrane
FR2543018B1 (fr) *	1983-03-22	1985-07-26	Oreal	Procede de preparation de vesicules lipidiques par vaporisation de solvants
IT1238343B (it) *	1989-10-16	1993-07-13	Cesalpino Andrea Fond	Procedimento per la preparazione di vaccini capaci di generare non solo la risposta immune dei linfociti t helper,ma anche un'efficace risposta di linfociti t citotossici,e vaccini con queste caratteristiche
RU94040856A (ru) *	1992-03-03	1996-08-20	Дайити Фармасьютикал Ко.	Вакцина для перорального введения
US6096291A (en) *	1996-12-27	2000-08-01	Biovector Therapeutics, S.A.	Mucosal administration of substances to mammals
AU2014368594B2 (en) *	2013-12-19	2020-03-05	Janssen Vaccines & Prevention B.V.	Improved formulations for virosomes

1975
- 1975-09-29 GB GB39857/75A patent/GB1564500A/en not_active Expired
1976
- 1976-09-28 JP JP51116473A patent/JPS5244228A/ja active Pending
- 1976-09-28 HU HU76WE542A patent/HU176180B/hu unknown
- 1976-09-28 AU AU18164/76A patent/AU514848B2/en not_active Expired
- 1976-09-28 SE SE7610708A patent/SE7610708L/ not_active Application Discontinuation
- 1976-09-28 CA CA262,165A patent/CA1079634A/en not_active Expired
- 1976-09-28 BE BE171023A patent/BE846681A/xx not_active IP Right Cessation
- 1976-09-28 DD DD7600195018A patent/DD127598A5/xx unknown
- 1976-09-28 BG BG034303A patent/BG34181A3/xx unknown
- 1976-09-28 ES ES451923A patent/ES451923A1/es not_active Expired
- 1976-09-28 NL NL7610736A patent/NL7610736A/xx not_active Application Discontinuation
- 1976-09-28 FR FR7629064A patent/FR2325387A1/fr active Granted
- 1976-09-28 PL PL1976192701A patent/PL103082B1/pl unknown
- 1976-09-28 ZA ZA00765817A patent/ZA765817B/xx unknown
- 1976-09-28 DE DE19762643641 patent/DE2643641A1/de not_active Withdrawn

Also Published As

Publication number	Publication date
DD127598A5 (de)	1977-10-05
JPS5244228A (en)	1977-04-07
BG34181A3 (en)	1983-07-15
CA1079634A (en)	1980-06-17
ZA765817B (en)	1978-05-30
AU1816476A (en)	1978-04-06
GB1564500A (en)	1980-04-10
BE846681A (fr)	1977-03-28
SE7610708L (sv)	1977-03-30
FR2325387A1 (fr)	1977-04-22
ES451923A1 (es)	1977-08-16
DE2643641A1 (de)	1977-04-14
AU514848B2 (en)	1981-03-05
HU176180B (en)	1980-12-28
FR2325387B1 ( )	1980-06-27
NL7610736A (nl)	1977-03-31

Publication	Publication Date	Title
US4196191A (en)	1980-04-01	Biological preparations
KR970005004B1 (ko)	1997-04-11	뮤우신에 대하여 친화력을 갖는 리포조옴
US4235871A (en)	1980-11-25	Method of encapsulating biologically active materials in lipid vesicles
US4241046A (en)	1980-12-23	Method of encapsulating biologically active materials in lipid vesicles
US4148876A (en)	1979-04-10	Biological preparations
JP2933931B2 (ja)	1999-08-16	医療用のリポソームおよび薬物含有リポソームのエアゾールの小粒子
PL103082B1 (pl)	1979-05-31	Sposob wytwarzania nowego preparatu antygenowego
CN107708671B (zh)	2020-12-04	包含钴卟啉-磷脂缀合物和聚组氨酸标签的纳米结构
ES2536689T3 (es)	2015-05-27	Membranas víricas reconstituidas funcionalmente que contienen adyuvante
JPH11500727A (ja)	1999-01-19	新規なカチオン性脂質およびそれらの使用
JP2856547B2 (ja)	1999-02-10	リガンド・レセプター組成物の製造方法
JPH11512712A (ja)	1999-11-02	生物学的に活性な物質を細胞に送達するためのエマルジョンおよびミセル処方物
JPH07505639A (ja)	1995-06-22	自己構築ポリヌクレオチド送達システム
DK2023896T3 (en)	2016-10-03	A composition for the inactivation of enveloped viruses
CA1333359C (en)	1994-12-06	Dental therapy by vesicle delivery
Stoffel et al.	1975	Carbon-13 nuclear magnetic resonance studies on the lipid organization in enveloped virions (vesicular stomatitis virus)
JPS6362490B2 ( )	1988-12-02
AU2023274159A1 (en)	2024-03-21	COMPOSITION FOR IN-VIVO DELIVERING mRNA CONTAINING MODIFIED NUCLEOTIDE
JPS61274739A (ja)	1986-12-04	燐脂質小胞と、それをフゾジエニツクにする方法
JP7635149B2 (ja)	2025-02-25	コバルトポルフィリン・リン脂質コンジュゲート及びポリヒスチジンタグを含むナノ構造体
US11207421B2 (en)	2021-12-28	Nanostructures comprising cobalt porphyrin-phospholipid conjugates and polyhistidine-tags
JP2005281146A (ja)	2005-10-13	リポソームからなる遺伝子導入用キャリア
CN121731217A (zh)	2026-03-27	脂质体、药物脂质体复合物及其制备方法和应用
JPH06504523A (ja)	1994-05-26	サクシニミジル部分を有するリン脂質類似体小胞
TW202410883A (zh)	2024-03-16	用於體內遞送包含經修飾的核苷酸的ｍＲＮＡ的組合物